Other approved or investigational agents with known anti-CMV activity. Request by patient. Investigator determines continuing the study would be detrimental to the patient. Patient becomes CMV DNA PCR positive and refuses Step 2 randomization. Patient experiences CMV EOD and refuses Step 3 registration.
Patient requires medication with anti-CMV activity.
Patient does not meet laboratory criteria for Step 2 within 12 weeks of CMV DNA positivity. Refusal to participate in Step 3. Requirement for medication with anti-CMV activity. All patients meeting discontinuation criteria should have evaluations as described in the protocol. Always watch for outdated information.